COMMD5

Across TCGA pan-cancer cohorts, COMMD5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COMMD5 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher COMMD5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated COMMD5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where COMMD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.956	0.772	.012	13	view →
PDAC	DFS	Tertile	III,IV	0.998	0.515	.002	10	view →
LUAD	OS	Median	III,IV	0.765	0.255	.012	2	view →
LSCC	OS	Quartile	All	0.818	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COMMD5–HNSC (OS)

Open the HNSC breakdown →